January 28th, 2010 -- Posted in Prostacet |
Scientists at The Institute of Cancer Research (ICR) suppose that Patients could be tested for these genetic abnormalities to alleviate referee the zeal of healing they should receive. The span used a Technique called fluorescence in situ hybridisation (FISH) to pump Three precise genetic alterations in Prostate Cancer samples from 308 patients: sacrifice of the PTEN gene and rearrangement of the ERG or ETV1 genes. Previous Studies have shown that ERG gene rearrangements crop up commonly in Prostate Cancer as do deletions of all or factor of the PTEN gene, but the combined Results of these abnormalities on Survival in a big union of Patients has not once been examined. Study lead author and ICR scientist Dr Alison Reid says the carriage or scarcity of these abnormalities has a major crashing on a Patient’s risk of Dying from Prostate Cancer.
“In this Study, we found that Patients who had none of these genetic alterations had a permissible prediction - 85.5 per cent were still energetic after 11 years,” Dr Reid says. “Happily, the bulk of Prostate Cancer sufferers in this Study, 54 per cent, were in this category.” “But the prophecy was unfortunately much worse for the six per cent of Patients who had mislaid the PTEN gene but had neither an ERG nor ETV1 gene rearrangement.
continue reading »
Tags:
cancer,
genetic,
patients,
Prostate,
research
Related posts
December 5th, 2009 -- Posted in Prostate |
Drs. Neal Shore and E. David Crawford presented Results for Prostate-Specific Antigen (PSA) Recurrence from the additional investigation of subordinate end points of Biochemical Recurrence chew out in a Phase III focal deliberate over of FIRMAGON® (monthly for Injection) or monthly leuprolide in Patients during the head year of Treatment. Prostate Cancer Patients who received FIRMAGON 240/80 mg/month had a Recurrence deserve of 7.7% during the word go year of care compared with 12.9% of Patients treated with leuprolide 7.5 mg/month (p=0.05). Patients being treated with FIRMAGON also had longer hour to Recurrence compared with those on leuprolide (p=0.04). Results of the PSA inquiry were presented in a broadsheet at the 10th Annual Meeting of the Society of Urologic Oncology, held in conjunction with the World Urological Oncology Federation, on December 3 in Bethesda, MD.
About the Study In the Phase III multicenter, randomized, open-label endeavour comparing degarelix with leuprolide, Prostate Cancer Patients (n=610) were randomized to a starting Dosage of degarelix 240 mg for one month, followed by monthly prolongation Doses of 80 mg (n=207) or 160 mg (n=202), or leuprolide 7.5 mg/month (n=201). Results showed that degarelix is as serviceable as leuprolide in reducing and sustaining castrate Levels of Testosterone.(1),(2) Suppression of Testosterone to castrate Levels occurred significantly faster in Patients receiving degarelix than in those receiving leuprolide.(1),(2) The chew over also showed that degarelix achieves faster crack-down of luteinizing Hormone and follicle-stimulating Hormone.(1),(2) PSA Recurrence was defined as two consecutive increases in PSA of 50% compared with nadir and greater than or peer to 5 ng/mL on two consecutive measurements at least two Weeks apart.
continue reading »
Tags:
degarelix,
firmagon,
leuprolide,
patients,
recurrence
Related posts
November 17th, 2009 -- Posted in Prostacet |
UroToday.com - Gonadotrophin-releasing Hormone (GnRH) agonists are currently the ’standard of care’ for androgen deprivation Group Therapy (ADT) in. Improvements in ADT would have a great value for many Patients.
The agonists are associated with an sign Testosterone surge, which delays castration and may fuel Tumor wen and move ‘Clinical flare’ in Patients with symptomatic Advanced Disease. 1 Consequences of blaze involve skeletal pain, ureteral obstruction, and spinal string compression. GnRH receptor blockers (antagonists) are a unripe Grade of advocate that stand via abrupt and competitive blockade of Pituitary GnRH receptors.
continue reading »
Tags:
leuprolide,
patients,
testosterone
Related posts
November 3rd, 2009 -- Posted in Prostacet |
Proton shine Therapy can be safely delivered to men with Prostate Cancer and has minutest urinary and rectal secondary Effects, according to a Study presented November 2, 2009, at the American Society for Radiation Oncology’s 51st Annual Meeting in Chicago. Researchers sought to govern if delivering higher Doses of dispersal with proton Treatment would cause first pernicious side Effects to urinary Function within the genitourinary plan (GU) Function and rectal go within the gastrointestinal (GI) System. “Proton psychoTherapy is becoming more popular as a Treatment for Prostate Cancer, but it is unclear at this station whether the long-term outcomes with proton cure will be better than those achieved with other Treatments. These protocols were designed to authenticate benchmark Results with proton analysis given with relatively high daily Doses.
At this Point, we can estimate that Early toleration of proton Therapy has been excellent, with a very low berate of urinary and rectal toxicity,” Nancy Mendenhall, M.D., a sanctum author and Medical vice-president of the University of Florida Proton Therapy Institute in Jacksonville, Fla., said.
continue reading »
Tags:
cancer,
patients,
proton,
radiation,
rectal,
therapy
Related posts
October 20th, 2009 -- Posted in Prostacet |
“This callow PSA assay may change the executive of Patients who have been treated with Surgery for Prostate Cancer,” said William J. Catalona, M.D., professor of Urology at the Feinberg School and Number one of the Clinical Prostate Cancer Program at the Lurie Cancer Center.
He was the ahead to describe that the PSA test, a dense Blood test, could be Euphemistic pre-owned as a Screening gismo for Prostate Cancer. “Studies have shown that postoperative diffusion cure given prehistoric to Patients with adverse Pathology, called adjuvant Radiation, reduces the Recurrence censure and improves Survival,” Catalona said. “Because the ‘nano-PSA assay’ is more sore than the Present commercially nearby PSA Tests, it may appropriate physicians to end adjuvant emission for Patients destined to have a life-threatening Tumor Recurrence.” The about is an Early indicator of how nanotechnology can be cast-off to improve Medical Diagnostics and ancient Cancer Detection.
continue reading »
Tags:
assay,
cancer,
levels,
patients
Related posts
July 27th, 2009 -- Posted in Prostate |
The lightning gain in the use of Screening using (PSA) Testing has led to a open-handed Number of men diagnosed with , many of who do not be Short Treatment. In these cases, establish Clinical monitoringor Active surveillanceis often Recommended. If course of the Cancer occurs during effectual surveillance, may undergo Radical Therapy. While occupied surveillance may delay or even Avoid the workable adverse side Effects of Radical Treatment, it could also cause psychogenic harm in Patients because they must live with untreated Cancer.
Data on the Levels of such potentially amongst men on animated surveillance are lacking, however. Roderick van den Bergh, (MD), of the Erasmus Medical Center, in Rotterdam, the Netherlands, and colleagues assessed Levels of and angst in a grouping of recently diagnosed Prostate Cancer Patients on quick surveillance. They sent 150 men questionnaires to appraise uncertainty about their curing decision, as well as Levels of pit and angst surrounded by these men. A Total of 129 questionnaires were completed and returned an standard of 2.7 months after Diagnosis.
continue reading »
Tags:
active,
cancer,
patients,
Prostate,
surveillance
Related posts
June 22nd, 2009 -- Posted in Prostate |
Men who consumed compounds in unskilled tea showed a reduction in serum markers predictive of Prostate Cancer progression, U.S. researchers said. James A. Cardelli of the Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center-Shreveport, and colleagues conducted an open-label, single-arm, period II Clinical attempt to dictate the slang shit of Short-term supplementation with verdant tea’s busy compounds on serum biomarkers in Patients with Prostate Cancer.
The biomarkers incorporate hepatocyte proliferation factor, vascular endothelial crop constituent and Prostate exact Antigen. HGF and VEGF are morality prognostic indicators of Metastatic Disease, Cardelli said. The Retreat included 26 men, ages 41-72 years, diagnosed with Prostate Cancer and scheduled for pinko Prostatectomy — Rubbing out of the Prostate. Patients consumed four capsules containing Polyphenon E until the prime before Surgery – four capsules are a kind to about 12 cups of normally brewed concentrated inexperienced tea, Cardelli said.
continue reading »
Tags:
cancer,
capsules,
cardelli,
center,
patients,
Prostate
Related posts
June 15th, 2009 -- Posted in Prostate |
Department of Family and Community Medicine, Eastern Virginia Medical School, 825 Fairfax Avenue, Norfolk, VA 23507, USA. This Email greet is being protected from spam bots, you desideratum Javascript enabled to Direction it Cancer-Specific mortality is projected to be only 1% in 15 years in approximately 75% of Patients with screen-detected localized Prostate Cancer (LPC). Nearly 94% of Patients select care even though Therapy damages Health-Related superiority of life. No observations are obtainable apropos what Survival further Patients expected from Treatment.
Objectives: A self-administered mailed examine was sent to 184 men with newly diagnosed LPC to ask Patients about expected Survival with curing versus observation.
continue reading »
Tags:
cancer,
expected,
patients,
survival
Related posts
May 23rd, 2009 -- Posted in Prostacet |
PHILADELPHIA, May 23 (UPI) — U.S. researchers have Linked adverse oxygen Levels in Prostate Tumors to Cancer Recurrence. Using a statistical nonesuch that accounted for such hazard factors as Tumor Grade, Prostate-Specific Antigen up to date and Tumor size, researchers at the Fox Chase Cancer Center in Philadelphia found bawl oxygen – hypoxia — in the Tumor before healing to be a significant affluent predictor of an snowball in PSA Levels.
PSA Levels are considered markers of Tumor Recurrence in Prostate Cancer. Dr. Aruna Turaka of Fox Chase Cancer Center in Philadelphia and colleagues custom-built a enquiry to Study the quantity of oxygen that Prostate Tumors and non-Cancerous muscle accumulation were receiving on 57 Patients with scanty or transitional jeopardy of Cancer – just before the Patients received a arrangement of localized diffusion analysis known as Brachytherapy.
continue reading »
Tags:
cancer,
levels,
patients,
Prostate,
researchers,
tumor,
tumors
Related posts
May 18th, 2009 -- Posted in Prostacet |
Section of Urology, Kalmar County Hospital, Kalmar, Sweden. Radical Prostatectomy (RP) has become the most standard curing for localized Prostate Cancer in Sweden. Outcome is outrageously righteousness for pT2 Stage with Gleason succeed in seducing 6 or less, but more than every fourth operated persistent will have a pT3 Stage on full Amount sample histology. According to several reports the risk of Biochemical Recurrence is altogether high, especially in Stage pT3, on agile surveillance after Surgery alone. In 1994 the authors recognized this certainty at their Clinic and unhesitating to Apply a new multimodality healing concept.
During 10 years, between 1 January 1995 and 1 January 2005, 98 pT3 Patients were treated with a triple treatment: 8 months of neoadjuvant/adjuvant luteinizing Hormone-releasing Hormone (LH-RH) analogue Treatment, RP and pressing adjuvant radiotherapy (RT) 3 months after RP. RT was delivered to 60 Gy in 30 fractions to the Prostatic bed to all the Patients. The cumulative imperil of headway was purposeful with the Kaplan-Meier Method.
continue reading »
Tags:
adjuvant,
months,
patients
Related posts
Next »
